Wells Fargo & Company Issues Pessimistic Forecast for Heartflow (NASDAQ:HTFL) Stock Price

Heartflow (NASDAQ:HTFL) had its price objective decreased by stock analysts at Wells Fargo & Company from $38.00 to $35.00 in a report issued on Thursday,Benzinga reports. The brokerage presently has an “overweight” rating on the stock. Wells Fargo & Company‘s price objective suggests a potential upside of 34.51% from the stock’s current price.

HTFL has been the topic of a number of other research reports. Weiss Ratings restated a “sell (d)” rating on shares of Heartflow in a research note on Monday, December 29th. Canaccord Genuity Group reaffirmed a “buy” rating and issued a $40.00 price objective on shares of Heartflow in a research report on Monday, March 9th. Five investment analysts have rated the stock with a Buy rating, two have issued a Hold rating and one has assigned a Sell rating to the stock. Based on data from MarketBeat.com, the stock currently has an average rating of “Moderate Buy” and an average target price of $37.67.

Heartflow Price Performance

Shares of NASDAQ:HTFL opened at $26.02 on Thursday. The business’s 50-day moving average is $26.86 and its 200 day moving average is $30.41. Heartflow has a 1 year low of $20.13 and a 1 year high of $41.22. The firm has a market capitalization of $2.23 billion and a P/E ratio of -14.38.

Insider Buying and Selling at Heartflow

In other news, insider Campbell Rogers sold 65,153 shares of the company’s stock in a transaction on Thursday, February 12th. The shares were sold at an average price of $24.49, for a total value of $1,595,596.97. Following the sale, the insider directly owned 76,034 shares of the company’s stock, valued at $1,862,072.66. This represents a 46.15% decrease in their position. The transaction was disclosed in a legal filing with the Securities & Exchange Commission, which is accessible through the SEC website. Also, major shareholder Bain Capital Life Sciences Inv sold 2,000,000 shares of the firm’s stock in a transaction on Wednesday, February 4th. The stock was sold at an average price of $28.05, for a total transaction of $56,100,000.00. Following the transaction, the insider directly owned 10,448,158 shares of the company’s stock, valued at approximately $293,070,831.90. This trade represents a 16.07% decrease in their position. Additional details regarding this sale are available in the official SEC disclosure. Insiders sold 2,127,399 shares of company stock valued at $59,295,771 over the last quarter.

Hedge Funds Weigh In On Heartflow

Several institutional investors and hedge funds have recently modified their holdings of HTFL. Wellington Management Group LLP boosted its stake in shares of Heartflow by 20.8% in the fourth quarter. Wellington Management Group LLP now owns 5,894,070 shares of the company’s stock worth $171,812,000 after buying an additional 1,014,006 shares during the last quarter. Baillie Gifford & Co. purchased a new position in Heartflow during the third quarter valued at approximately $101,182,000. Bamco Inc. NY raised its position in Heartflow by 86.2% during the fourth quarter. Bamco Inc. NY now owns 2,303,877 shares of the company’s stock valued at $67,158,000 after acquiring an additional 1,066,371 shares in the last quarter. Schusterman Interests LLC acquired a new position in Heartflow in the third quarter valued at approximately $65,274,000. Finally, Capricorn Investment Group LLC purchased a new stake in Heartflow in the 4th quarter worth approximately $48,178,000.

Key Headlines Impacting Heartflow

Here are the key news stories impacting Heartflow this week:

• Positive Sentiment: Q4 revenue beat and strong top‑line growth — HeartFlow reported revenue of $49.13M vs consensus $46.58M, up ~40.5% year‑over‑year, signaling accelerating adoption and top-line momentum. MarketBeat: Q4 results & transcript
• Positive Sentiment: Bullish analyst move — Canaccord raised its price target to $43 and maintained a Buy rating, implying a sizable upside and providing supportive institutional sentiment. Benzinga: Canaccord price target raise
• Neutral Sentiment: Analysts cut targets but stayed positive — JPMorgan lowered its PT from $40 to $35 but kept an Overweight rating, signaling confidence in the business even while trimming valuation assumptions. Benzinga: JPMorgan PT change
• Neutral Sentiment: Wells Fargo also trimmed its PT (from $38 to $35) but maintained an Overweight rating, another sign of cautious optimism. Benzinga: Wells Fargo PT change
• Neutral Sentiment: Independent analysis available — Seeking Alpha published a piece reviewing HeartFlow’s strategy and growth opportunities; useful for investors analyzing the longer‑term thesis. Seeking Alpha: HeartFlow: Getting Into The Flow
• Negative Sentiment: EPS miss and continued losses — HeartFlow reported GAAP EPS of ($0.29) vs consensus ($0.16), missing estimates and underscoring margin pressure and ongoing unprofitability (PE remains negative). MarketBeat: EPS miss / earnings details
• Negative Sentiment: Valuation and trend considerations — Despite the rally, the stock remains below its 50‑day and 200‑day moving averages and carries a wide range of analyst targets, indicating continued volatility and mixed near‑term sentiment. Benzinga: HTFL earnings & estimates

About Heartflow

HeartFlow, Inc (NASDAQ: HTFL) is a medical technology company that develops non-invasive diagnostic solutions for coronary artery disease. The company’s core offering translates coronary CT angiography (CTA) data into a patient-specific, three-dimensional physiological model of the coronary arteries. Using advanced image processing and computational modeling, HeartFlow’s analysis estimates fractional flow reserve (FFR) values throughout the coronary tree to identify ischemia-producing lesions without the need for invasive pressure-wire measurements.

HeartFlow’s cloud-based service integrates with clinical workflows: clinicians submit coronary CTA images and receive a detailed, color-coded 3D map and report that highlights lesion-specific FFR values and physiological impact.